Advances in Targeted Therapies for Triple-Negative Breast Cancer

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• Hormone receptor-positive (HR+) and HER2-positive breast cancers have seen improved outcomes due to targeted therapies.
• Triple-negative breast cancer (TNBC) treatment remains limited to cytotoxic chemotherapy.
• TNBC accounts for 10-15% of all breast cancer diagnoses.

Purpose of the Study:

• To review recent therapeutic innovations for triple-negative breast cancer (TNBC).
• To highlight the potential for molecularly delineating TNBC into subgroups with targetable oncogenic drivers.
• To discuss emerging targeted treatments beyond traditional chemotherapy.

Main Methods:

• Literature review of recent therapeutic innovations for TNBC.
• Focus on advancements in targeted therapies including PARP inhibitors, PI3K pathway inhibitors, immune checkpoint inhibitors, and CDK inhibitors.
• Analysis of TNBC biology for identification of targetable oncogenic drivers.

Main Results:

• While HR+ and HER2+ breast cancers benefit from targeted therapies, TNBC treatment options are still evolving.
• Emerging therapies show promise for molecularly targeting specific TNBC subgroups.
• Key therapeutic classes under investigation include PARP inhibitors, PI3K pathway inhibitors, immune checkpoint inhibitors, and CDK inhibitors.

Conclusions:

• Enhanced characterization of TNBC biology is crucial for developing targeted treatments.
• Targeted therapies such as PARP, PI3K, immune checkpoint, and CDK inhibitors represent promising avenues for TNBC treatment.
• Future research aims to move beyond chemotherapy by identifying and targeting specific oncogenic drivers in TNBC.